Cumberland Pharmaceuticals Stock Performance
| CPIX Stock | USD 3.36 0.20 5.62% |
The firm shows a Beta (market volatility) of 2.41, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cumberland Pharmaceuticals will likely underperform. At this point, Cumberland Pharmaceuticals has a negative expected return of -0.25%. Please make sure to confirm Cumberland Pharmaceuticals' standard deviation, potential upside, as well as the relationship between the Potential Upside and day median price , to decide if Cumberland Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Cumberland Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's forward indicators remain fairly strong which may send shares a bit higher in August 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 4.71 | Five Day Return (5.32) | Year To Date Return 59.64 | Ten Year Return (42.86) | All Time Return (78.85) |
Last Split Factor 2:1 | Last Split Date 2007-07-06 |
1 | Acquisition by Krogulski Kenneth of tradable shares of Cumberland Pharmaceuticals at 4.79 subject to Rule 16b-3 | 04/30/2025 |
2 | Cumberland Pharmaceuticals First Quarter 2025 Earnings EPS US0.084 | 05/08/2025 |
3 | Acquisition by Kazimi A J of tradable shares of Cumberland Pharmaceuticals at 4.02 subject to Rule 16b-3 | 05/09/2025 |
4 | Acquisition by Kazimi A J of tradable shares of Cumberland Pharmaceuticals at 4.92 subject to Rule 16b-3 | 05/19/2025 |
5 | Acquisition by Kazimi A J of tradable shares of Cumberland Pharmaceuticals at 5.41 subject to Rule 16b-3 | 05/20/2025 |
6 | Acquisition by Kazimi A J of tradable shares of Cumberland Pharmaceuticals at 5.05 subject to Rule 16b-3 | 05/21/2025 |
7 | Acquisition by Kazimi A J of tradable shares of Cumberland Pharmaceuticals at 5.1 subject to Rule 16b-3 | 05/22/2025 |
8 | Acquisition by Kazimi A J of tradable shares of Cumberland Pharmaceuticals at 5.14 subject to Rule 16b-3 | 05/23/2025 |
9 | NEW STUDY FINDS CALDOLOR SAFE AND EFFECTIVE FOR OPIOID-SPARING | 05/27/2025 |
10 | Acquisition by Kazimi A J of tradable shares of Cumberland Pharmaceuticals at 5.68 subject to Rule 16b-3 | 05/28/2025 |
11 | Acquisition by Kazimi A J of tradable shares of Cumberland Pharmaceuticals at 5.66 subject to Rule 16b-3 | 05/29/2025 |
12 | Acquisition by Kazimi A J of tradable shares of Cumberland Pharmaceuticals at 4.93 subject to Rule 16b-3 | 05/30/2025 |
13 | Acquisition by Jones James of tradable shares of Cumberland Pharmaceuticals at 5.41 subject to Rule 16b-3 | 06/06/2025 |
14 | Acquisition by Krogulski Kenneth of tradable shares of Cumberland Pharmaceuticals at 4.61 subject to Rule 16b-3 | 06/23/2025 |
15 | Acquisition by Krogulski Kenneth of tradable shares of Cumberland Pharmaceuticals at 3.91 subject to Rule 16b-3 | 06/24/2025 |
16 | Acquisition by Krogulski Kenneth of tradable shares of Cumberland Pharmaceuticals at 3.27 subject to Rule 16b-3 | 06/25/2025 |
17 | Acquisition by Krogulski Kenneth of tradable shares of Cumberland Pharmaceuticals at 2.71 subject to Rule 16b-3 | 06/26/2025 |
18 | Acquisition by Krogulski Kenneth of tradable shares of Cumberland Pharmaceuticals at 2.6 subject to Rule 16b-3 | 06/27/2025 |
19 | Caroline Young of Cumberland Pharmaceuticals buys CPIX shares By Investing.com - Investing.com India | 07/11/2025 |
20 | What drives Cumberland Pharmaceuticals Inc. stock price - Unmatched market performance - jammulinksnews.com | 07/22/2025 |
| Begin Period Cash Flow | 18.3 M | |
| Total Cashflows From Investing Activities | 57.8 B |
Cumberland | Build AI portfolio with Cumberland Stock |
Cumberland Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 497.00 in Cumberland Pharmaceuticals on April 25, 2025 and sell it today you would lose (161.00) from holding Cumberland Pharmaceuticals or give up 32.39% of portfolio value over 90 days. Cumberland Pharmaceuticals is currently does not generate positive expected returns and assumes 8.7183% risk (volatility on return distribution) over the 90 days horizon. In different words, 78% of stocks are less volatile than Cumberland, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cumberland Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cumberland Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cumberland Pharmaceuticals, and traders can use it to determine the average amount a Cumberland Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0292
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CPIX |
Estimated Market Risk
| 8.72 actual daily | 78 78% of assets are less volatile |
Expected Return
| -0.25 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Cumberland Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cumberland Pharmaceuticals by adding Cumberland Pharmaceuticals to a well-diversified portfolio.
Cumberland Pharmaceuticals Fundamentals Growth
Cumberland Stock prices reflect investors' perceptions of the future prospects and financial health of Cumberland Pharmaceuticals, and Cumberland Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cumberland Stock performance.
| Return On Equity | -0.12 | ||||
| Return On Asset | -0.027 | ||||
| Profit Margin | (0.08) % | ||||
| Operating Margin | 0.11 % | ||||
| Current Valuation | 46.2 M | ||||
| Shares Outstanding | 14.96 M | ||||
| Price To Earning | (16.05) X | ||||
| Price To Book | 1.83 X | ||||
| Price To Sales | 1.24 X | ||||
| Revenue | 37.87 M | ||||
| Gross Profit | 34.65 M | ||||
| EBITDA | 182.42 K | ||||
| Net Income | (6.44 T) | ||||
| Cash And Equivalents | 18.22 M | ||||
| Cash Per Share | 1.24 X | ||||
| Total Debt | 20.57 M | ||||
| Debt To Equity | 0.50 % | ||||
| Current Ratio | 1.80 X | ||||
| Book Value Per Share | 1.92 X | ||||
| Cash Flow From Operations | (612.19 B) | ||||
| Earnings Per Share | (0.24) X | ||||
| Market Capitalization | 50.87 M | ||||
| Total Asset | 75.58 M | ||||
| Retained Earnings | (23.97 M) | ||||
| Working Capital | 4.83 M | ||||
| Current Asset | 66.96 M | ||||
| Current Liabilities | 11.69 M | ||||
About Cumberland Pharmaceuticals Performance
Evaluating Cumberland Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Cumberland Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cumberland Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 221.68 | 324.74 | |
| Return On Tangible Assets | (0.11) | (0.11) | |
| Return On Capital Employed | (0.16) | (0.15) | |
| Return On Assets | (0.09) | (0.08) | |
| Return On Equity | (0.28) | (0.27) |
Things to note about Cumberland Pharmaceuticals performance evaluation
Checking the ongoing alerts about Cumberland Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cumberland Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cumberland Pharmaceuticals generated a negative expected return over the last 90 days | |
| Cumberland Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 37.87 M. Net Loss for the year was (6.44 T) with profit before overhead, payroll, taxes, and interest of 34.65 M. | |
| Cumberland Pharmaceuticals currently holds about 18.22 M in cash with (612.19 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.24. | |
| Roughly 42.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: What drives Cumberland Pharmaceuticals Inc. stock price - Unmatched market performance - jammulinksnews.com |
- Analyzing Cumberland Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cumberland Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Cumberland Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cumberland Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cumberland Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cumberland Pharmaceuticals' stock. These opinions can provide insight into Cumberland Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Cumberland Stock Analysis
When running Cumberland Pharmaceuticals' price analysis, check to measure Cumberland Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cumberland Pharmaceuticals is operating at the current time. Most of Cumberland Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cumberland Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cumberland Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cumberland Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.